(turmeric), and have received much attention due to their pleiotropic anticancer properties. Recent evidence suggests that curcumin and analogs prevent the activation of a variety of signaling pathways, including the MAPK, PI3K/Akt, and NF-kB pathways, resulting in the induction of apoptosis, prevention of proliferation, and suppression. In addition to these processes, curcumin has been shown to enhance the efficacy of the conventional anti-cancer modalities such as radiation and chemotherapy. By suppressing the expression of matrix metalloproteinases (MMPs), which are enzymes that break down the extracellular matrix and promote cancer cell invasion and metastasis, curcumin also demonstrates anti-metastatic qualities. Inflammation and the advancement of cancer are linked to the NF-κB signaling pathways, which are also suppressed by curcuminoids. Along with these processes, curcumin has demonstrated the ability to improve the effectiveness of traditional cancer treatments, including radiation and chemotherapy. It increases the sensitivity of cancer cells to various therapies, which enhances the therapeutic results. However, curcumin's low bioavailability limits its therapeutic use. Its anticancer potency may be increased, and this restriction may be overcome due to recent developments in drug delivery technologies, such as curcumin-loaded nanoparticles. Since they can target several different molecular pathways and improve the effectiveness of current treatments, curcuminoids are a promising family of chemicals for the prevention and treatment of cancer.
BACKGROUND: Polypharmacy and potential drug-drug interactions (pDDIs) are major challenges in the management of elderly patients with multiple comorbidities, often leading to adverse drug events and increased healthcare burden. AIM: This study aimed to determine the prevalence and patterns of polypharmacy and pDDIs among elderly patients attending Yenepoya Medical College and Hospital, Mangalore, India. METHODS: A cross-sectional study was conducted from January to June 2023 among 310 elderly patients (aged ≥60 years) selected through simple random sampling from both in-patient and out-patient departments. Polypharmacy was defined as the concurrent use of ≥5 medications, and excessive polypharmacy as ≥9 medications. Drug interaction screening was performed using UpToDate and Medscape interaction checker tools. Statistical analyses included descriptive statistics, t-tests, chi-square tests, and regression analysis, with significance set at p < 0.05. RESULTS: The prevalence of polypharmacy was slightly higher in females (53.84%) than males (51.94%), with the highest rates observed in the 70-79 age group (48.88%). Most patients experienced moderate (50%) drug interactions. A significant gender difference was observed in the number of drugs prescribed at treatment (p = 0.0032), but not at discharge. Regression analysis identified gender (p = 0.018) and inpatient status (p < 0.001) as significant predictors of polypharmacy, while age was not (p = 0.719). CONCLUSION: This study reveals a high prevalence of polypharmacy among elderly patients attending Yenepoya Medical College and Hospital. Polypharmacy was found to be more prevalent among female patients, older age groups, and in inpatient wards. The distribution of drug interactions revealed a pervasive nature across various degrees, with moderate interactions being the most common. Future research should use larger samples, and diverse populations to better understand polypharmacy, drug interactions, and outcomes.
Long-term, flexible therapy strategies are needed for chronic diseases like cardiovascular ailments, diabetes, and chronic kidney disease and they have to deal with patient heterogeneity, changing physiological states and privacy constraints. This research suggests a framework for privacy-preserving and personalized artificial intelligence that combines Federated Learning (FL), a Res-HyperTransformerNet deep prediction model, Personalized Multi-Agent Reinforcement Learning (PMARL) and Explainable Artificial Intelligence (XAI) for adaptive chronic disease management. The framework is structured with two main aims: (i) to create an accurate and privacy-aware predictive model for chronic disease risk using diverse data sources, and (ii) to permit adaptive, individual therapy optimization through multi-agent reinforcement learning. Federated learning is utilized to conduct the training of Res-HyperTransformerNet over distributed Internet of Medical Things (IoMT) nodes without the requirement of transferring raw patient data. The embeddings that are created from patient data are then passed on to a PMARL module, where several agents optimize therapy dimensions like medications, diet, physical activity, and mental health interventions independently. To make the clinical support more understandable, the SHAP-based explainability method is used for both predictive and decision-making parts. The framework is tested using two public datasets—the CDC Chronic Disease dataset and the UCI Chronic Kidney Disease Risk Factor dataset. The performance is measured by employing classification metrics (accuracy, precision, recall, F1-score, MCC) as well as reinforcement learning metrics (reward score, convergence steps, episode return) and federated system metrics (communication overhead, convergence rounds, and training time). The experiments indicate that the proposed framework demonstrated improved performance in terms of predictive accuracy and policy convergence speed compared to the baseline deep learning and reinforcement learning models, and at the same time it is more cost-effective when it comes to communication in a federated setting. This means that the proposed method suggests the potential of being a reproducible and open AI framework for adaptive chronic disease therapy management. The combination of ResNet and Transformer blocks, i.e., Federated Res-HyperTransformerNet, achieved strong performance in both datasets, namely CDC Chronic Disease (Dataset 1) and UCI CKD Risk Factor (Dataset 2). The obtained accuracy for Dataset 1 was 98.61% and for Dataset 2, it was 97.75%, under the conducted experimental settings.
Background and objective: Hyperemesis gravidarum (HG) is a condition that develops early in pregnancy, before 16 weeks of gestation, and is characterized by severe nausea and/or vomiting, inability to tolerate food and/or beverages, and substantial impairment of daily activities. Hyperemesis gravidarum can have obvious maternal and fetal consequences. This study aimed to assess the prevalence of HG, investigate its associated electrolyte and hematologic disturbances, and identify risk factors among pregnant women in Aljouf, Saudi Arabia. Methods: A retrospective observational case-control study was conducted using 200 medical records selected from a total of 9,090 records of pregnant women at the Maternity and Children Hospital in Aljouf, covering the period from November 2020 to November 2023. Results: The prevalence of hyperemesis gravidarum was 1.1% among the studied pregnant women. Patients diagnosed with hyperemesis gravidarum showed significantly lower body weight and BMI than controls. Nearly 48% of HG cases occurred in women aged 30-39 years, while 52% were in the first trimester. Furthermore, 36% of the affected women were primigravida, and 11% were pregnant with twins. Hypotension was observed in 35% of HG cases. Hyponatremia occurred in 29% of patients, hypokalemia in 21%, and hypochloremia in 24%. Hematological disturbances included increased Hb levels in 11% of cases, increased hematocrit in 12%, leukocytosis in 19%, and neutrophilia in 17% of the patients. Conclusion: Hypotension, electrolyte imbalance, and hematological disturbances are the primary consequences of HG. First-trimester pregnancy and low gestational age are the most important risk factors for HG. Strategies by healthcare centers and further research are needed to enhance the treatment, management, and prevention methods of HG.
Frontiers in Global Women s Health · مجلد 6 · 1707792-1707792
Background: Physical activity offers numerous health benefits and helps prevent various diseases, making it an essential component of a healthy lifestyle. Objective: This study aims to examine the barriers and enablers that affect female participation in physical activity. Methods: This was a cross-sectional quantitative study. The study questionnaire was adopted from a previous study. The survey was conducted online and completed by 668 Saudi women from across the country. Results: The study findings regarding low physical activity levels among Saudi women are concerning, as 72.2% of participants were classified as sedentary or physically inactive. The study revealed that age, employment status, and income were significant factors affecting engagement of women in physical activity. Moreover, barriers such as expensive gym memberships, a lack of women-only clubs, a lack of enjoyment in sports, and prolonged use of the same exercise devices prevented Saudi women from participating in physical activities. However, women reported exercising to boost their self-satisfaction and self-confidence, thereby promoting overall health. Conclusion: Saudi women exhibit a low level of physical activity. Barriers such as expensive gym memberships, a lack of women-only clubs, a lack of enjoyment in sports, prolonged use of the same exercise devices, and motivations related to self-satisfaction and self-confidence prevent Saudi women from practicing physical activities. Health system policymakers need to take action to increase physical activity levels and address these barriers.
physical activitybarriers to exercisesedentary behaviorSaudi women
International Journal of Clinical Pediatric Dentistry · مجلد 19 (6) · 779-793
Background: Dental caries is a common oral health problem that affects people all over the world. To detect and treat it early on, it is important to have a thorough understanding of its genesis and potential biomarkers. Objective: The objective of this systematic review is to answer the question: "Is there any role of immune status in the development of dental caries among children and adults, and is there any potential in using immunological markers for diagnosis, prognosis, and treatment of this condition?" Design: From 2016 to 2024, a thorough search approach adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria was used across several datasets (PROSPERO: CRD42024612045). To find pertinent publications, a total of 2,723 articles were searched using keywords associated with dental caries, immunity, and interventions. The inclusion criteria included papers that addressed the connection between immunity and the development of caries, interventions, and results, including alterations in basal metabolic rate (BMR), weight gain in patients, improvements in quality of life, and recurrence of carious lesions. Two reviewers independently extracted the data, assessed its quality, and assessed the risk of bias using validated instruments such as the Cochrane Risk of Bias tool and the Newcastle-Ottawa Scale. Results: The evaluation encompassed 10 articles in all, demonstrating noteworthy correlations between immunological indicators and dental caries. Results point to a favorable correlation between salivary immunoglobulin A (IgA) levels and the number of carious teeth, as well as an increase in proinflammatory cytokine concentrations in dental caries patients. Furthermore, the pulp tissue of dental caries patients has different bacterial communities and higher expression of proinflammatory cytokines, suggesting a possible connection between immune activation and dysbiosis. Conclusion: The findings highlight the significance of immune status/immunological indicators in the diagnosis and treatment of dental caries, emphasizing the necessity for additional study to corroborate these conclusions and improve treatment and preventative dental care practices. Clinical relevance: This work has got great relevance to pediatric dentists. The current work highlights a possible link between the immune status and the development of caries in pediatric and adult patients as well as the potential of immunological markers in the diagnosis, prognosis, and treatment of dental caries in both pediatric and adult patients. Prospero registration number: CRD42024612045.
Melasma is a chronic acquired hyperpigmentation disorder that often exerts a psychosocial burden on affected individuals. Although laser- and light-based therapies are pivotal third-line interventions for recalcitrant cases, clinical consensus regarding their comparative efficacy and long-term safety remains inconsistent. This systematic review and meta-analysis aimed to evaluate and synthesize evidence from randomized controlled trials (RCTs) on the efficacy and safety of various laser-based therapies for melasma. A literature search was performed using PubMed, Excerpta Medica Database (EMBASE), Cochrane Library, and Web of Science databases from inception to January 2026. RCTs and split-face comparative studies evaluating laser therapies versus placebo, topical agents, or alternative laser modalities were included. Data synthesis was performed using a random-effects model with Hartung-Knapp adjustment. The primary outcome was the mean difference (MD) in the reduction of the Melasma Area and Severity Index (MASI) score. The certainty of evidence was appraised using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Fifty-two studies, involving 1,058 participants, met the inclusion criteria. The overall pooled analysis showed a trend toward clinical improvement that was not statistically significant (MD: 0.70; 95% CI: -0.55, 1.95; p = 0.2682). Subgroup analysis by laser technology revealed that low-fluence Q-switched Nd:YAG (QSNY) (1064 nm) lasers provided a statistically significant reduction in melasma severity (MD 1.47; 95% CI: 0.08 to 2.85, p < 0.05), while picosecond lasers (MD -0.11; 95% CI: -0.79 to 0.57) and fractional lasers (MD 0.94; 95% CI: -0.84 to 2.71) did not significantly outperform control groups. Statistical heterogeneity was high across the evidence (I² = 96.2%). The overall certainty of evidence for the primary outcome was very low because of the lack of blinding and the high inconsistency. No serious adverse events were reported, although minor complications, such as transient erythema and localized burning, were common. Low-fluence QSNY laser therapy is an effective adjunctive modality for melasma management. However, due to high recurrence rates and variability in outcomes, it should be integrated into a multi-modal approach alongside strict photoprotection and topical depigmenting agents. Future research should prioritize the long-term follow-up and standardization of laser parameters across different skin phenotypes.
BACKGROUND: With the surge in scientific publication over the years, there is an exponential rise in predatory publishing. The aim of the current study was to assess predatory journals’ awareness among clinical and non-clinical researchers. METHODS: A cross-sectional study was conducted in a tertiary care hospital, affiliated university and the research center. Both males/females, physicians, professors, researchers, students, working in a hospital, university or a research center were enrolled. The primary outcome was the awareness of predatory journals, and to identify the predictors of awareness. The estimated sample size was 369. The survey consisted of 33 questions divided into five sections: (i) General information (ii) Research publications (iii) Awareness of predatory journals (iv) Open access (v) Journal selection. The questions were either yes/no or 5-point Likert scale. An electronic survey design was used for data collection. Variables were compared by aware and unaware groups using chi-square test. Logistic regression analysis was utilized to identify the predictors of awareness. Statistical analyses were performed using SAS version 9.4. RESULTS: Of the total 328 respondents, females were 178(54.4%), near half had bachelors/master’s degree 156(48.3%), 117(35%) were physicians, 37(11%) researchers, 17(5%) professors, and 38(12%) students. Half of the participants 167(50.9%) were aware of the term ‘predatory medical journals. Only 56(17%) reported knowing how to spot a predatory journal. 15(4.5%) have reported publishing in a predatory journal due to lack of knowledge (6/15; 40%), to meet a deadline (3/15; 20%), suggested by a colleague (3/15; 20%), or due to (1/15; 6.6%) fast publication process. Reported sources of information were; colleagues 141(42%), attending a course 78(24%), and spam emails 73(22%). 69(21%) respondents reported using Clarivate Master Journal List, 54(16%) SCImago Journal & Country Rank list, 48(15%) use DOAJ. 282(85%) didn’t hear of the educational website Think.Check.Submit. Age (p = 0.036), gender (p = 0.0007), qualification (p = 0.0002), profession (p = 0.01), working in a research center (p = 0.005), and professional training (p = 0.0006) were significantly different by predatory journal awareness. CONCLUSION: Publishing in a predatory medical journal is a global threat to the scientific community and academic integrity. Efficient steps need to be taken in order to address predatory journals’ invasion, and raising awareness.
Type 2 diabetes mellitus (T2DM) increases the risk of cardiovascular morbidity and end-stage renal disease. Renin-angiotensin-aldosterone system (RAAS) inhibitors, specifically angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), are standard therapies for organ protection. However, uncertainty remains regarding their comparative efficacy and the safety of combination therapy. This systematic review and meta-analysis aimed to compare the efficacy of ACEIs versus ARBs in reducing cardiovascular and renal events in patients with T2DM and to assess the safety of dual blockade. PubMed, EMBASE, and Cochrane databases were searched for randomized controlled trials (RCTs) published up to 2025 comparing ACEIs, ARBs, or their combination against placebo or active controls in T2DM patients. The primary outcome was a composite of cardiovascular death, myocardial infarction, stroke, and renal failure. Methodological quality was assessed using the Cochrane Risk of Bias 2 tool. Data were synthesized using frequentist pairwise and Bayesian network meta-analyses. Heterogeneity was explored via meta-regression, and trial sequential analysis (TSA) was used to assess the sufficiency of evidence. In total, 16 RCTs involving 47,406 participants were included. In pairwise analysis, both ACEIs (risk ratio (RR) = 0.87, 95% confidence interval (CI) = 0.81-0.94) and ARBs (RR = 0.90, 95% CI = 0.83-0.98) significantly reduced the risk of the primary composite endpoint compared to control. Network meta-analysis showed no statistically significant difference between ACEIs and ARBs (RR = 0.98, 95% CI = 0.88-1.09). Although ACEIs ranked slightly higher in probability for reducing all-cause mortality (surface under the cumulative ranking = 78% vs. 65%), this difference was not statistically significant. Dual blockade (ACEI + ARB) increased the risk of hyperkalemia (RR = 2.8) and acute kidney injury (RR = 1.7) without improving efficacy. Meta-regression identified baseline systolic blood pressure as a significant modifier of treatment benefit (p = 0.04). TSA indicated that the evidence for the RAAS blockade's benefit is conclusive. ACEIs and ARBs exhibit comparable efficacy in preventing cardiovascular and renal events in patients with T2DM, with a marginal mortality benefit favoring ACEIs. Dual blockade is associated with increased harm and is not recommended. Monotherapy with either agent remains the preferred strategy for organ protection.
ACE inhibitorsangiotensin receptor blockerstype 2 diabetesrenin-angiotensin-aldosterone system blockade
Digital Health · مجلد 12 · 20552076251406312-20552076251406312
Objective: The study's overarching goal is to improve E-health monitoring systems' precision and performance by developing and implementing an Rendezvous Data Processing Model (RDPM) that is compatible with IoT-cloud architecture. The approach solves a problem with current E-health systems; these systems frequently make incorrect or redundant suggestions because they depend too much on static analytic methods and isolated data augmentation. Methods: The RDPM system recommended improves real-time decision-making by digesting historical suggestions and present analytical flaws. Divided features and data streams allow it to validate new hypotheses by comparing them to earlier observations. The state learning process has been improved by earlier efforts to avoid errors and data duplication, the model must distinguish intervening and non-intervening data. Internet-connected sensors collect massive volumes of patient and environment data. Cloud analytics evaluates the system's precision using these data. Results: Experimental results show that RDPM reduces data interruptions, analytical errors, and recommendation ratios while improving decision correctness. The model shows that it can quickly interpret many input streams without compromising accuracy. Compared to IoT-based healthcare analytics, the RDPM improves suggestion accuracy and reduces computing redundancy. Conclusion: IoT-cloud technologies with the RDPM system establish an adaptive and scalable platform for sophisticated E-health monitoring. State learning and dynamic data validation allow RDPM to make more accurate and convenient health recommendations. This approach allows a healthcare system to self-improve, understand context, and manage massive, real-time datasets.
e-health monitoringIoT-cloud integrationstate learningreal-time decision making
ABSTRACT This research explores the capacity of phenyl styryl ketone derivatives to inhibit monoamine oxidase B (MAO‐B), a key enzyme associated with neurodegenerative disorders. From frontier molecular orbital (FMO) studies, reactivity parameters of the drug candidates were found out. Ligands were submitted to absorption, digestion, metabolism, excretion, and toxicity (ADMET) analysis to ensure their potential drugability and safety. To understand the electronic description of ligand interaction, natural bond orbital (NBO) analysis was conducted, and the presence of heteroatoms was proven crucial. The reduced density gradient (RDG) studies, together with molecular electrostatic surface potential (MESP) analysis, were able to provide the ligand's active sites and nature of interaction. Docking studies were conducted to study the interaction between the protein (P) and ligand (L) at the MAO‐B catalytic region, alongside a comparison with safinamide, a recognized MAO‐B inhibitor. Molecular dynamics (MD) simulations were utilized to examine the protein–ligand complex (PLC). The molecular mechanics Poisson–Boltzmann surface area (MM‐PBSA) method was applied to predict the binding affinity and interaction. We also analyzed structural stability, solvation, and decomposition. Of the four ligands examined, CHA_1.4 is found to be the most efficient. The contact map method was useful in identifying the key amino acids; in all the complexations we have considered, TYR398 has interacted most with the drug candidates. The finding was in agreement with the decomposition profile of the PLC. For the principal component analysis (PCA), topology formats and 100 ns MD trajectories are used to learn more about how proteins fold. Replicates were also done to validate the reported study and are represented as box‐whisker plots. The study's findings provide valuable insights for the development of new MAO‐B inhibitors.
monoamine oxidase B inhibitorsmonoamine oxidase Bneurodegenerative diseasesfrontier molecular orbitals
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed as antidiabetic agents, have emerged as candidate disease-modifying therapies for Parkinson’s disease (PD) and Alzheimer’s disease (AD), reflecting the widespread expression of GLP-1 receptors across neurons, glia, and the cerebral vasculature. This narrative review synthesizes mechanistic, clinical trial, and biomarker evidence for GLP-1 RAs in PD and AD, based on a literature search of PubMed, Embase, Scopus, and Web of Science, with ClinicalTrials.gov searched separately for trial protocols and results, through May 2026. Preclinical data implicate GLP-1 receptor agonism in anti-neuroinflammatory signaling, mitochondrial preservation, autophagy and proteostasis enhancement, anti-apoptotic effects, synaptic plasticity, cerebrovascular protection, and glymphatic clearance. Clinical evidence in PD is mixed and agent- and formulation-dependent: the phase II Exenatide-PD trial reported a motor benefit that persisted after washout (∼3.5-point between-group difference in MDS-UPDRS Part III), and the phase II LIXIPARK trial (lixisenatide) reported a significant 3.08-point between-group difference (95% CI 0.86–5.30; p = 0.007) favoring lixisenatide, whereas the larger, longer phase III Exenatide-PD3 trial, using an extended-release weekly formulation, found no significant effect on the same endpoint (adjusted coefficient 0.92; 95% CI −1.56 to 3.39; p = 0.47); oral semaglutide is under investigation in the ongoing phase II MOST-ABLE trial. In AD, the phase IIb liraglutide (ELAD) trial did not achieve statistical benefit on either its primary imaging endpoint (cerebral glucose metabolic rate; p = 0.14) or on most secondary cognitive measures, and the phase III semaglutide trials EVOKE and EVOKE+ did not meet their primary CDR-SB endpoint (estimated difference −0.08, 95% CI −0.35 to 0.20, p = 0.57 in EVOKE; 0.10, 95% CI −0.17 to 0.38, p = 0.46 in EVOKE+), despite biomarker signals including reductions in cerebrospinal fluid tau species and inflammatory markers. Comparative pharmacology reveals substantial heterogeneity in central nervous system penetration, receptor engagement, and systemic bioavailability across exenatide, liraglutide, semaglutide, and the imbalanced GLP-1/GIP co-agonist tirzepatide, complicating cross-agent extrapolation. Persistent challenges include separating direct neuroprotection from indirect metabolic and cardiovascular benefit, limited characterization of brain drug exposure, trial durations that may be short relative to the expected latency of a disease-modifying effect, and the absence of validated response biomarkers. We conclude that although the mechanistic and epidemiological rationale for GLP-1 RAs in neurodegeneration remains biologically plausible, current trial evidence does not yet support their use outside clinical trials, irrespective of comorbid diabetes status; future studies should prioritize earlier intervention, biomarker-guided patient selection, adequately powered subgroup analyses, and brain-penetrant formulations.
Kho-Kho is a high-intensity traditional sport characterized by rapid directional changes, relay-based movement patterns, and sustained postural demands, requiring well-developed agility, balance, and functional movement capacity. This study examined pre-post changes in functional movement, postural stability, and agility during a short-term camp-based functional strength and balance training period in male and female national-level Kho-Kho players. This single-arm, pre-post interventional trial included 60 national-level Kho-Kho players (30 males, 30 females) who participated in a two-week intensive functional strength and balance training program conducted during a training camp. No concurrent control group was included. Pre- and post-training assessments included the Functional Movement Screen (FMS), static balance under open- and closed-eye conditions, dynamic balance on both and single limbs, and agility performance using SEMO and Illinois tests. Linear sprint speed was assessed using a 40 m run test. Sex-based differences were examined using independent t tests, and two-factor ANOVA was used to examine differences according to time point, sex, and their interaction for selected performance outcomes. Significant pre-post changes were observed in FMS composite scores for both sexes ( p ≤ 0.001, η 2 p = 0.66). Static balance scores changed favorably under both visual conditions (open eyes: p ≤ 0.001, η 2 p = 0.82; closed eyes: p ≤ 0.001, η 2 p = 0.76). Dynamic balance showed significant time-related changes in overall analysis for both-feet and single-limb conditions ( p ≤ 0.001, η 2 p = 0.25 and 0.35, respectively), although within-sex analysis showed that the female single-foot condition did not change significantly. Agility test times showed significant pre-post reductions in SEMO and Illinois tests ( p ≤ 0.001, η 2 p = 0.66 and 0.68), whereas the 40 m run test showed no significant changes ( p = 0.28). Significant overall differences between male and female players were identified for dynamic balance on both feet ( p = 0.007, η 2 p = 0.12) and agility outcomes (SEMO: p ≤ 0.001, η 2 p = 0.37; Illinois: p ≤ 0.001, η 2 p = 0.38). During the short-term structured camp-based functional strength and balance training period, favorable pre-post changes were observed in functional movement, postural stability, and agility among national-level Kho-Kho players. Because of the single-arm pre-post design, the absence of a concurrent control group, and possible agility-test familiarization effects, the findings describe changes observed over time and do not establish that the training program caused the observed changes. Controlled studies are required to determine the independent contribution of the training program. Trial registration : ClinicalTrials.gov, NCT06602895; retrospectively registered on 17 September 2024, after participant enrolment and commencement of the study.
Diabetic neuropathy (DN) is a multifactorial complication of diabetes mellitus driven by chronic hyperglycemia, insulin resistance, and disturbed metabolic homeostasis, leading to progressive injury of both the peripheral and central nervous systems. This study investigated whether L-serine supplementation could attenuate DN through dose-dependent metabolic and neuroprotective mechanisms in a high-fat diet (HFD) plus streptozotocin (STZ)-induced diabetic rat model. Male Wistar rats (n = 8 per group) were allocated to five groups: normal control (NC), diabetic control (DC), pioglitazone (PIO; 1.5 mg/kg/day), low-dose L-serine (S1; 200 mg/kg/day), and high-dose L-serine (S2; 400 mg/kg/day). After 60 days of oral gavage, behavioural testing, glucose and insulin profiling, HOMA-IR calculation, brain histopathology, nerve growth factor (NGF) immunohistochemistry, and LC–MS/MS-based proteomic analysis of cerebral tissue were performed. Diabetic rats exhibited marked hyperglycaemia (355.33 ± 4.72 mg/dL), hyperinsulinaemia, severe insulin resistance (HOMA-IR 16.8 ± 3.2; a 14-fold increase), impaired thermal nociception, motor dysfunction, and pronounced neuronal degeneration. L-serine supplementation significantly improved metabolic status: S1 reduced HOMA-IR by 77.4% and S2 by 87.5% relative to diabetic controls (p < 0.001). High-dose L-serine produced greater improvements in thermal sensitivity, motor coordination (rotarod latency 26.67 ± 1.52 s vs. 16.1 ± 0.85 s in DC; p < 0.05), and NGF expression (8.6-fold increase vs. DC). Histopathology confirmed attenuation of neuronal injury and gliosis in both treatment groups. Exploratory, group-level proteomic profiling identified dose-specific molecular signatures: S1 was predominantly associated with carbohydrate, lipid, and biosynthetic pathways, whereas S2 was associated with synaptic, neurotransmission-related, and proteostasis pathways. Within the constraints of an exploratory design—group-level pooled proteomics, analysis of cerebral rather than peripheral-nerve tissue, and only two doses—these findings indicate that L-serine attenuates the metabolic and behavioural features of experimental diabetic neuropathy and generates the testable hypothesis of dose-dependent neuro-metabolic remodelling. The proteomic signatures are hypothesis-generating and require orthogonal validation before any mechanistic or translational inference can be drawn.